小细胞肺癌化疗前后血清VEGF的变化及临床意义

Clinical significance of serum vascular endothelial growth factor in patients with small cell lung cancer

目的:探讨化疗前后小细胞肺癌(SCLC)患者血清血管内皮生长因子(sVEGF)水平及临床意义。方法:用酶联免疫吸附法(ELISA)测定48例SCLC患者化疗前后sVEGF的变化,并与健康志愿者做对照。结果:化疗前SCLC组sVEGF水平为(351.57±30.93)μg/ml,健康志愿者(128.83±13.90)μg/ml,差别有统计学意义(P<0.01)。化疗后sVEGF为(274.99±38.20)μg/ml,明显低于化疗前(P<0.01),但仍然高于健康志愿者(P<0.01)。结论:SCLC组sVEGF水平明显高于健康志愿者,化疗可以降低SCLC患者sVEGF水平,但仍高于健康志愿人,加用抗血管生成的分子靶向治疗是必要的。

Objective： To study the change and clinical significance of serum vascular endothelial growth factor（sVEGF） in patients with small cell lung cancer（SCLC） before and after chemotherapy. Methods： sVEGF was measured in 48 cases patients with SCLC by quantitative enzyme-linked immunosorbent assay（ ELISA） and was compared with healthy volunteers. Results： Before chemotherapy sVEGF in patients with SCLCs was （351.57±30.93）μg/ml,the healthy volunteers was （128.83±13.90）μg/ml （P0.01）.sVEGF after chemotherapy was （274.99±38.20）μg/ml higher than healthy volunteers （P0.01）. Conclusion： sVEGF in patients with SCLC before chemotherapy was higher than that of healthy volunteers.sVEGF in patients with SCLC decreaed after chemotherapy,but is still higher than healthy volunteers.It is necessary to use anti-angiogenesis of targeted therapy.